Emil Bulatov
Emil Bulatov
Verified email at
Cited by
Cited by
Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation
E Bulatov, A Ciulli
Biochemical Journal 467 (3), 365-386, 2015
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
A Titov, A Petukhov, A Staliarova, D Motorin, E Bulatov, O Shuvalov, ...
Cell death & disease 9 (9), 897, 2018
Application of CAR-T cell therapy beyond oncology: autoimmune diseases and viral infections
E Zmievskaya, A Valiullina, I Ganeeva, A Petukhov, A Rizvanov, E Bulatov
Biomedicines 9 (1), 59, 2021
Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment
A Titov, A Valiullina, E Zmievskaya, E Zaikova, A Petukhov, R Miftakhova, ...
Cancers 12 (1), 125, 2020
Adoptive immunotherapy beyond CAR T-cells
A Titov, E Zmievskaya, I Ganeeva, A Valiullina, A Petukhov, ...
Cancers 13 (4), 743, 2021
Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors
E Bulatov, R Sayarova, R Mingaleeva, R Miftakhova, M Gomzikova, ...
Cell Death Discovery 4 (1), 103, 2018
Key Players In The Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
V Chasov, R Mirgayazova, E Zmievskaya, R Khadiullina, A Valiullina, ...
Frontiers in Oncology 10, 1460, 2020
Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
R Mirgayazova, R Khadiullina, V Chasov, R Mingaleeva, R Miftakhova, ...
Genes 11 (6), 704, 2020
Small molecule modulators of RING-type E3 ligases: MDM and Cullin families as targets
E Bulatov, A Zagidullin, A Valiullina, R Sayarova, A Rizvanov
Frontiers in pharmacology 9, 450, 2018
Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2)
E Bulatov, EM Martin, S Chatterjee, A Knebel, S Shimamura, ...
Journal of Biological Chemistry 290 (7), 4178-4191, 2015
Binding and purification of plasmid DNA using multi-layered carbon nanotubes
II Shakhmaeva, ER Bulatov, OV Bondar, DV Saifullina, M Culha, ...
Journal of biotechnology 152 (3), 102-107, 2011
Knowns and unknowns about CAR-T cell dysfunction
A Titov, Y Kaminskiy, I Ganeeva, E Zmievskaya, A Valiullina, ...
Cancers 14 (4), 1078, 2022
Discovery of nanomolar-affinity pharmacological chaperones stabilizing the oncogenic p53 mutant Y220C
JR Stephenson Clarke, LR Douglas, PJ Duriez, DI Balourdas, AC Joerger, ...
ACS Pharmacology & Translational Science 5 (11), 1169-1180, 2022
Promising new tools for targeting p53 mutant cancers: Humoral and cell-based immunotherapies
V Chasov, M Zaripov, R Mirgayazova, R Khadiullina, E Zmievskaya, ...
Frontiers in Immunology 12, 707734, 2021
Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases
E Bulatov, A Valiullina, R Sayarova, A Rizvanov
Immunology Letters 202, 44-51, 2018
Effect of size and protein environment on electrochemical properties of gold nanoparticles on carbon electrodes
TI Abdullin, OV Bondar, II Nikitina, ER Bulatov, MV Morozov, ...
Bioelectrochemistry 77 (1), 37-42, 2009
Novel Isatin-based activator of p53 transcriptional functions in tumor cells
R Mirgayazova, R Khadiullina, R Mingaleeva, V Chasov, M Gomzikova, ...
Molecular Biology Research Communications 8 (3), 119, 2019
Ubiquitin-Proteasome System: Promising Therapeutic Targets in Autoimmune and Neurodegenerative Diseases
E Bulatov, S Khaiboullina, H José dos Reis, A Palotás, K Venkataraman, ...
Bionanoscience, 2016
Design, synthesis and biological evaluation of 2-quinolyl-1, 3-tropolone derivatives as new anti-cancer agents
EA Gusakov, IA Topchu, AM Mazitova, IV Dorogan, ER Bulatov, ...
RSC advances 11 (8), 4555-4571, 2021
Serendipitous SAD solution for DMSO-soaked SOCS2-elonginC-elonginB crystals using covalently incorporated dimethylarsenic: insights into substrate receptor conformational …
MS Gadd, E Bulatov, A Ciulli
PloS one 10 (6), e0131218, 2015
The system can't perform the operation now. Try again later.
Articles 1–20